Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort

Martinez-Calle, Nicolas; Kirkwood, Amy A.; Lamb, Maxine; Smith, Alex; Khwaja, Jahanzaib; Manos, Kate; Shrubsole, Caroline; Gray, Nicola; Lewis, Katharine; Tivey, Ann; Bishton, Mark J.; Hawkes, Eliza; Ahearne, Matthew J.; Osborne, Wendy; Collins, Graham P.; Illidge, Timothy; Linton, Kim M.; Cwynarski, Kate; Burton, Cathy; Fox, Christopher P.

Abstract

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine practice, to serve as a benchmark analysis for comparison BV-CHP efficacy in routine practice. Methods: Patients aged 16 years or older with sALCL treated in seven UK and Australian centres and from 14 additional centres from the UK Haematological Malignancy Research Network database (n = 214). Treatment allocation was clinician choice and included best supportive care (BSC). Main outcomes were time to treatment failure (TTF) and overall survival (OS). Multivariable analysis for predictors of both TTF and OS was also undertaken. Results: The median age 52 years (range 16–93), 18% ECOG ≥ 3 and 40% of cases were ALK positive. CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) was employed in 152 (71%) of patients and CHOEP (CHOP + etoposide) in 4% of patients. For CHOP-treated patients overall response rate (ORR) was 65% and complete response (CR) 47%. Only 9% of patients underwent autologous stem cell transplant (ASCT). With 57 months median follow-up, 4-year TTF and OS were 41.2% (95% CI 33.1–49.1) and 58.9% (95% CI 50.3–66.5) respectively. Multivariable analysis showed ALK+ status was independently associated with superior TTF (HR 0.36, 95% CI 0.21–0.63) but not OS (0.44, 95% CI 0.18–1.07). Discussion: We present a retrospective analysis with mature follow-up of one of the largest multicentre populations of sALCL available, comparable to similar large retrospective studies. ALK status remains a strong predictor of outcomes. Conclusion: These data serve as a robust benchmark for BV-CHP as the new standard of care for sALCL. Similar real-world evidence with BV-CHP will be desirable to confirm the findings of ECHELON-2.

Citation

Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

• Journal Article Type: Article
• Acceptance Date: Apr 28, 2021
• Online Publication Date: May 26, 2021
• Publication Date: Jul 1, 2021
• Deposit Date: Feb 10, 2023
• Publicly Available Date: Feb 10, 2023
• Journal: Advances in Therapy
• Print ISSN: 0741-238X
• Electronic ISSN: 1865-8652
• Publisher: Springer Science and Business Media LLC
• Peer Reviewed: Peer Reviewed
• Volume: 38
• Issue: 7
• Pages: 3789-3802
• DOI: https://doi.org/10.1007/s12325-021-01764-0
• Keywords: Pharmacology (medical); General Medicine
• Public URL: https://nottingham-repository.worktribe.com/output/17084042
• Publisher URL: https://link.springer.com/article/10.1007/s12325-021-01764-0